If you're bullish on Chewy, the company won't offer hyper-growth, but it is a solid business with steady long-term prospects in a vast industry. It's a low-risk stock, but also low-reward in the long ...

A new Wegovy pill is now available nationwide, giving adults a daily tablet option instead of weekly shots for weight loss ...

When endocrinologist Dan Bessesen, MD, looked online and saw how easy it would be for him to purchase a weight loss drug from ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $48.0, a high estimate of $52.00, ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

Following a lengthy legal battle in 2024, City Drug Pharmacy will be moving to a new location on Lincolnway next week. The ...

Plans show Chewy Vet Care in Tamaya Market, the shopping center anchored by Sprouts Farmers Market, at northeast Beach and ...

The U.S. Food and Drug Administration approved the Wegovy pill in late December 2025 for adults who are obese or overweight ...

The new products feature playful designs, including holiday-themed Lamb Chops Nicholas Rice is a Senior Editor for PEOPLE Magazine. He began working with the brand as an Editorial Intern in early 2020 ...

Chewy beat Q3 earnings by 39% with net income surging 1,415% to $59.2M from $3.9M last year. This marks the fourth straight quarter of sustained profitability with net income between $59M and $62M.

To provide investors with additional information regarding our financial results, we have disclosed in this earnings release the following non-GAAP financial measures: Adjusted EBITDA: defined as net ...

Investing.com -- Chewy, Inc. (NYSE:CHWY) reported third-quarter fiscal 2025 results that exceeded analyst expectations. After initially sending shares up 3.9% in premarket trading, the stock is now ...